Immunocore Holdings plc (IMCR)

Market Cap	1.68B
Revenue (ttm)	356.15M
Net Income (ttm)	-20.31M
Shares Out	50.39M
EPS (ttm)	-0.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	553,885
Open	33.58
Previous Close	33.81
Day's Range	33.10 - 34.47
52-Week Range	23.15 - 39.33
Beta	0.77
Analysts	Buy
Price Target	57.00 (+70.58%)
Earnings Date	Nov 5, 2025

About IMCR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 493
• Stock Exchange: NASDAQ
• Ticker Symbol: IMCR
• Website: https://www.immunocore.com

Financial Performance

In 2024, Immunocore Holdings's revenue was $310.20 million, an increase of 24.37% compared to the previous year's $249.43 million. Losses were -$51.09 million, -7.60% less than in 2023.

Analyst Summary

According to 8 analysts, the average rating for IMCR stock is "Buy." The 12-month stock price target is $57.0, which is an increase of 70.58% from the latest price.

Price Target

$57.0

(70.58% upside)

Analyst Consensus: Buy